Clinical Trials
3 trialsNCT07618390 2026-06-01
A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT07340658 2026-04-02
SIE-3
Rovi Pharmaceuticals Laboratories
Phase 3 Not yet recruiting
NCT06849947 2025-12-24
Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer
Samsung Medical Center
Phase 2 Not yet recruiting